Long-term treatment of deep-vein thrombosis with low-molecularweight heparin: An update of the evidence

Thrombosis and Haemostasis

Volumn 110, Issue 1, 2013, Pages 14-22

  Hull, Russell D ^a   Townshend, Grace ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b Watermeadow Medical   (United Kingdom)

Author keywords

Deep vein thrombosis; Low molecular weight heparin; Post thrombotic syndrome; Tinzaparin

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; BEMIPARIN; COUMARIN; DABIGATRAN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; RIVAROXABAN; TINZAPARIN; WARFARIN;

ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; ECZEMA; EDEMA; FOLLOW UP; HUMAN; HYPERPIGMENTATION; LEG ULCER; LIPODERMATOSCLEROSIS; LONG TERM CARE; META ANALYSIS; NEOPLASM; PATIENT SATISFACTION; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECANALIZATION; RECURRENT DISEASE; SYSTEMATIC REVIEW (TOPIC); VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; EUROPE; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOSIS;

EID: 84879633829     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-12-0931     Document Type: Article

References (49)

1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (Suppl 2): e419S-94S.
2. van der Heijden JF, Hutten BA, Büller HR, et al. Vitamin K antagonists or lowmolecular- weight heparin for the long-term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2002; 1: CD002001.
3. Andras A, Sala Tenna A, Crawford F. Vitamin K antagonists or low-molecularweight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2012 Oct 17; 10: CD002001. doi:10.1002/14651858.CD002001.pub2.
4. Cardiovascular Disease Educational and Research Trust, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (Guidelines according to scientific evidence). Int Angiol 2006; 25: 101-161.
5. Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: A systematic review. Am J Med 2011; 124: 756-765.
6. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-197.
7. Das SK, Cohen AT, Edmondson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996; 20: 521-526.
8. Lopaciuk S, Bielska-Falda H, Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999; 81: 26-31.
9. Gónzalez-Fajardo JA, Arreba E, Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999; 30: 283-292.
10. Veiga F, Escriba A, Maluenda MP, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000; 84: 559-564.
11. López-Beret P, Orgaz A, Fontcuberta J, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001; 33: 77-90.
12. Kakkar VV, Gebska M, Kadziola Z, et al. Bemiparin Investigators. Low-molecular- weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost 2003; 89: 674-680.
13. Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 2005; 29: 638-650.
14. Hull RD, Pineo GF, Brant RF, et al. Self-managed long-term low-molecularweight heparin therapy: the balance of benefits and harms. Am J Med 2007; 120: 72-82.
15. Hull RD, Pineo GF, Brant R, et al. Home therapy of venous thrombosis with long-term LMWH versus usual care: Patient satisfaction and post-thrombotic syndrome. Am J Med 2009; 122: 762-769.
16. Romera A, Cairols MA, Vila-Coll R, et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009; 37: 349-356.
17. Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R, et al. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism. Ann Vasc Surg 2010; 24: 628-639.
18. Laporte S, Bertoletti L, Romera A, et al. Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: A meta-analysis of 5 randomized trials in non-cancer and cancer patients. Thromb Res 2012; 130: 853-858.
19. Pérez-de-Llano LA, Leiro-Fernández V, Golpe R, et al. Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study. Blood Coagul Fibrinolysis 2010; 21: 744-749.
20. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-3083.
21. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
22. Lee AY, Levine MN, Baker RI, et al; CLOT investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
23. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-1735.
24. Hull RD, Pineo GF, Brant RF, et al; LITE Trial Investigators. Long-term LMWH versus usual-care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-1072.
25. Deitcher SR, Kessler CM, Merli G, et al; ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12: 389-396.
26. Akl EA, Labedi N, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011 Jun 15; (6): CD006650. doi:10.1002/14651858.CD006650.pub3.
27. Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11: 56-70.
28. Lyman GH, Khorana AA, Falanga A, et al; American Society of Clinical Oncology. American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
29. Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2011; 22 (Suppl 6): vi85-92.
30. Imberti D, Agnelli G, Ageno W, et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER registry. Haematologica 2008; 93: 273-278.
31. Debourdeau P, Beckers M, Gérome P, et al. How to improve the implementation of guidelines on cancer-related thrombosis. Expert Rev Anticancer Ther 2011; 11: 473-483.
32. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
33. Bauersachs R, Berkowitz SD, Brenner B, et al.; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
34. Buller HR, Prins MH, Lensing AWA, et al.; EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
35. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl 6); 454S-545S.
36. Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698-707.
37. Kahn SR, Partsch H, Vedantham S, et al., on behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of postthrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost 2009; 7: 879-883.
38. Nicolaides AN, Allegra C, Bergan J, et al. Consensus Statement. Management of chronic venous disorders of the lower limbs: Guidelines according to scientific evidence. Int Angiol 2008; 27: 1-59.
39. Chitsike RS, Rodger MA, Kovacs MJ, et al. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. J Thromb Haemost 2012; 10: 2039-2044.
40. Daskalopoulos ME, Daskalopoulou SS, Prezas L, et al. Three-year follow-up of long-term deep venous thrombosis treatment with the low molecular weight heparin tinzaparin. Angiology 2006; 25 (Suppl 1): 76.
41. Daskalopoulos ME, Daskalopoulou SS, Liapis CD. Tinzaparin in longterm treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2007; 34: 353-354.
42. González-Fajardo JA, Martin-Pedrosa M, Castrodeza J, et al. Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. J Vasc Surg 2008; 48: 953-959.
43. Hull R, Butcher P. Value of patient self-assessment in the diagnosis and monitoring of post-thrombotic syndrome: the Patient-Tracked Symptoms questionnaire. Clin Appl Thromb Hemost 2012; 18: 345-350.
44. Cook DJ, Guyatt GH, Juniper E, et al. Interviewer versus self-administered questionnaires in developing a disease-specific, health-related quality of life instrument for asthma. J Clin Epidemiol 1993; 46: 529-534.
45. Cohen SB, Strand V, Aguilar D, et al. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. Rheumatology 2004; 43: 704-711.
46. Ballard KD, Seaman HE, de Vries CS, et al. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study-Part 1. Br J Obst Gynecol 2008; 115: 1382-1391.
47. Fransen GA, Janssen MJ, Muris JW, et al. Measuring the severity of upper gastrointestinal complaints: does GP assessment correspond with patients' self-assessment? Fam Pract 2007; 24: 252-258.
48. Evangelou E, Tsianos G, Ioannidis JP. Doctors' versus patients' global assessments of treatment effectiveness: empirical survey of diverse treatments in clinical trials. Br Med J 2008; 336: 1287-1290.
49. Noble S, Finlay I. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 2005; 19: 197-201.